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In Brief
Flaveny et al. design a liver-X-receptor
(LXR) inverse agonist SR9243 that
induces LXR-corepressor interaction.
SR9243 displays broad anti-tumor
activity and a favorable safety profile by
selectively targeting the Warburg effect
and lipogenesis.
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http://dx.doi.org/10.1016/j.ccell.2015.05.007SUMMARYMalignant cells exhibit aerobic glycolysis (the Warburg effect) and become dependent on de novo lipogen-
esis, which sustains rapid proliferation and resistance to cellular stress. The nuclear receptor liver-X-receptor
(LXR) directly regulates expression of key glycolytic and lipogenic genes. To disrupt these oncogenic meta-
bolism pathways, we designed an LXR inverse agonist SR9243 that induces LXR-corepressor interaction.
In cancer cells, SR9243 significantly inhibited the Warburg effect and lipogenesis by reducing glycolytic
and lipogenic gene expression. SR9243 induced apoptosis in tumors without inducing weight loss, hepato-
toxicity, or inflammation. Our results suggest that LXR inverse agonists may be an effective cancer treatment
approach.INTRODUCTION
Metabolism in cancer cells is primarily glycolytic even when ox-
ygen is abundant (Warburg et al., 1927). Aerobic glycolysis or the
Warburg effect is well characterized and has been shown to be
driven by mitochondrial defects, oncogenic stimuli, hypoxia,
and aberrantly enhanced expression of glycolytic enzymes (De-
Berardinis et al., 2008; Warburg et al., 1927; Yeung et al., 2008).
In particular, elevated glycolytic gene expression is pervasive in
cancers of the breast, colon, prostate, and lung. Oncogenes
such as mTOR, c-MYC, and hypoxia-inducible factor 1 (HIF-1)
promote glycolytic activity by upregulating expression of glyco-
lytic enzymes including phosphofructokinase 1 (PFK1), hexoki-
nases, and pyruvate dehydrogenase kinase-3 (Dang et al.,
1997; Jung et al., 2011; Koshiji and Huang, 2004; Lu et al.,
2008). In addition, expression of glycolysis-stimulating genesSignificance
A number of small molecules that target the Warburg effect an
clinical treatments because of off-target effects such as exce
in vivo. Here we describe the anti-cancer properties of an L
targeted treatments, SR9243 selectively induces apoptosis in c
nificant anti-tumor activity without overt toxicity, inflammation
onstrates that LXR inverse agonists hold significant promise a
42 Cancer Cell 28, 42–56, July 13, 2015 ª2015 Elsevier Inc.such as PFK1 and phosophofructokinase-2 (PFK2) are strongly
associated with highly aggressive and drug-resistant tumor
types (DeBerardinis et al., 2008; Phan et al., 2014). Conversely,
the tumor suppressor P53 has been shown to block cancer
cell growth by suppressing glucose consumption, preventing
the downregulation of mitochondrial aerobic respiration, inhibit-
ing NADPH production, and disrupting pentose phosphate
synthesis (Yeung et al., 2008). Therefore, the Warburg effect is
a central component of the metabolic reprogramming involved
in cancer etiology.
Glycolysis is less energy efficient compared to aerobic respi-
ration because it produces significantly fewer molecules of
ATP. However, by providing a surplus of metabolic substrates
for analplerosis that would be unavailable through normal aero-
bic respiration, the Warburg effect confers a selective survival
advantage to cancer cells. Substrates produced are funneledd lipogenesis have been developed but none have become
ssive weight loss, anorexia, high toxicity, and low efficacy
XR inverse agonist SR9243. Unlike previously developed
ancer cells but spares non-malignant tissues, exhibiting sig-
, or weight loss. The favorable safety profile of SR9243 dem-
s prospective clinical treatments.
into other metabolic pathways such as de novo lipid synthesis
(lipogenesis), nucleotide production and amino acid synthesis,
all of which are indispensable for rapid cancer cell growth.
Lactate, produced in abundance in tumors, is instrumental in
altering the intracellular redox balance, which promotes cancer
cell invasiveness (Bonuccelli et al., 2010; Martinez-Outschoorn
et al., 2011; Vander Heiden et al., 2009). Therefore, the Warburg
effect functions as the metabolic foundation of oncogenic
growth, tumor progression, and tumor resistance to treatment.
Despite displaying elevated glycolytic gene expression, cancer
cells within the tumor microenvironment can have distinct
metabolic profiles depending on pH and oxygen availability
(Dang, 2007; Fritz et al., 2010; Huang et al., 2012; Vander Heiden
et al., 2009; Yeung et al., 2008). This metabolic plasticity
allows cancer cells to evade cell death. Despite the variety of
‘‘druggable’’ targets identified, most glycolysis inhibitors show
substantial toxicity in normal tissues and limited therapeutic
applications in select cancer types (Pelicano et al., 2006).
The surplus glycolysis metabolites produced by the Warburg
effect are integrated into lipogenesis and other metabolic path-
ways in tumor cells. Glycolysis products are used to synthesize
short-, medium-, and long-chain fatty acids that are fundamental
building blocks for cell membranes and organelles. Typically,
cancer cells show elevated expression of lipogenesis enzymes
and endogenous production of lipids, whereas normal cells
obtain lipids primarily from exogenous sources (Vander Heiden
et al., 2009). Like glycolysis, lipogenic enzyme expression is
enhanced in tumors via oncogenic signaling. Although both
pathways are linked, compared to tumor glycolysis, lipogenesis
is not regulated by changes within the tumor microenvironment
such as pH and the availability of oxygen (Blancher and Harris,
1998). Lipids are synthesized by enzymes such as fatty acid syn-
thase (FASN), stearoyl-CoA desaturase (SCD1), and acetyl-CoA
carboxylase-1 (ACC1) acting downstream of glycolysis. Lipo-
genesis also facilitates immune system evasion and intercellular
signaling that promote tumor growth (Phan et al., 2014). Lipid
metabolites also provide valuable reducing power within the
low nutrient and highly oxidative microenvironment of tumors
(Carracedo et al., 2013; Zaytseva et al., 2012). Accordingly, lipo-
genic gene expression directly correlates with cancer aggres-
siveness, staging, and drug resistance (Notarnicola et al.,
2006, 2012; Ogino et al., 2009; Zaytseva et al., 2012). Increased
expression of FASN, SCD1, and ACC1 as well as the sterol-reg-
ulatory element binding protein-1c (SREBP1c), a transcription
factor that regulates lipogenic gene expression, is associated
with numerous forms of cancer (Furuta et al., 2010; Mason
et al., 2012). Lipogenesis inhibitors that block FASN, ACC1,
SCD1, and SREBP1c activity have been shown to reduce prolif-
eration and induce apoptosis in cancer cells (Chaje`s et al., 2006;
Mason et al., 2012; Notarnicola et al., 2006, 2012; Scaglia et al.,
2009). However, clinically viable therapies that effectively block
lipogenesis in vivo have not been forthcoming due to adverse
side effects such as anorexia and severe weight loss (Clegg
et al., 2002; Tu et al., 2005).
The liver-X-receptors, LXRa and LXRb (NR1H3 and NR1H2,
respectively) are nuclear receptors and key regulators of lipid,
cholesterol, and carbohydrate metabolism and homeostasis
(Kim et al., 2009; Laffitte et al., 2003; Wang et al., 2008; Zhao
et al., 2012). LXRb is ubiquitously expressed, whereas LXRa isexpressed in macrophages, liver, adipose, adrenal, intestinal,
and lung tissue. Both isoforms form obligate heterodimers with
the retinoid-X-receptor (RXR) and bind to endogenous agonists
such as the oxysterols 22(R)-hydroxycholesterol and 24(S)-hy-
droxycholesterol (Baranowski, 2008). LXRs regulate gene
expression by directly binding to LXR-responsive elements
(LXREs) within the promoter region of LXR-regulated genes. Un-
liganded LXRs selectively recruit corepressors such as nuclear
corepressor 1 and 2 (NCoR1 and SMRT) to form repressor com-
plexes at LXR-target gene promoters (Phelan et al., 2008; Wag-
ner et al., 2003). Through this mechanism, LXRs silence target-
gene expression in the absence of ligand activation. Conversely,
LXR agonist binding induces dissociation of corepressor com-
plexes and recruitment of LXR coactivators such as thyroid
hormone receptor-associated protein (TRAP220/DRIP-2). Coac-
tivator recruitment by ligand-activated LXRs initiates transcrip-
tion of LXR target genes such as glycolysis enzymes; PFK2
and GCK1 (Kim et al., 2009; Zhao et al., 2012) and lipogenesis
genes; SREBP1c, FASN, and SCD1 (Darimont et al., 2006; Jo-
seph et al., 2002; Zhang et al., 2006). Apart from their role in
glycolysis and lipogenesis gene regulation, LXRs are also known
to attenuate immune function as evidenced by LXR aberrant in-
flammatory signaling in LXR knockoutmice (Jamroz-Wisniewska
et al., 2007; Wo´jcicka et al., 2007). Moreover, LXR activation
stimulates cholesterol efflux via stimulation of activation of
ABC transporters (Beyea et al., 2007; Grefhorst et al., 2002).
Therefore, LXR has been the focus of a number of studies aimed
at developing cholesterol lowering drugs and treatments for
atherosclerosis. Unfortunately, LXR agonists are known to pro-
mote hepatic steatosis due to enhanced hepatic lipid synthesis,
which limits the potential use of LXR agonists as anti-arthero-
genic drugs in the clinic (Grefhorst et al., 2002; Viennois et al.,
2012).
Recent studies have highlighted the emerging role of LXR in
cancer metabolism, progression, and immune evasion (Russo,
2011; Villablanca et al., 2010). LXR agonists have been demon-
strated to significantly lower intracellular cholesterol levels in
cancer cells and therefore exhibit anti-neoplastic activity (Chuu
and Lin, 2010; Rough et al., 2010). As a result, LXR agonists
have been extensively investigated as pre-clinical anti-cancer
drugs. In contrast, tumor cells have been shown to secrete
LXR agonists that promote tumor immune evasion and survival
(Russo, 2011; Villablanca et al., 2010). Similarly, inhibition of
LXR activity also stimulated dendritic cell-mediated tumor cell
clearance, enhanced tumor rejection, and prevented tumor
recurrence in mice (Jamroz-Wisniewska et al., 2007; Russo,
2011; Villablanca et al., 2010). Furthermore, other investigations
suggest that synthetic LXR agonists may be somewhat antago-
nistic to chemotherapy treatment (Miller et al., 2011). LXR ago-
nists have been extensively investigated as anti-cancer agents
despite the deleterious side effects. However, targeted inhibition
of LXR activity to disrupt cancer growth has been left
unexplored.
Because LXR is a key regulator of glycolysis and lipogenesis,
enzymes that mediated the Warburg effect and tumor lipogen-
esis respectively, we decided to target LXR to disrupt cancer
cell growth. We designed an LXR inverse agonist, SR9243, to
lower the basal transcriptional activity of LXRs and promote
suppression of the Warburg effect and lipogenesis. WeCancer Cell 28, 42–56, July 13, 2015 ª2015 Elsevier Inc. 43
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Table 1. Calculated IC50 of SR9243 on the Viability of Cancer
Cells from Different Tissue Origins
Cancer Cell Line Tissue SR9243 IC50 (nM)
SW620 colon 40
HT-29 colon 104
DU-145 prostate 15
PC-3 prostate 61
NCI-H23 lung 72
HOP-62 lung 26
MIAPACA-2 pancreatic 18hypothesized that such a compound would have broad based
anti-cancer therapeutic activity and this is investigated in this
study.
RESULTS
SR9243 Inhibits LXR Activation by Enhancing
LXR-Corepressor Recruitment
With the goal of targeting the Warburg effect and lipogenesis in
cancer cells, we developed an LXR inverse agonist SR9243 (Fig-
ure 1A) that specifically targets LXR and downregulates LXR-
mediated gene expression to below basal levels (Figures 1B
and 1C). SR9243 was designed based on another LXR inverse
agonist, SR9238, which we recently described as a ‘‘liver-selec-
tive’’ LXR inverse agonist (Griffett et al., 2013). SR9238 contains
a rapidly metabolized ester moiety and SR9243 was designed to
provide systemic exposure. SR9243 dose-dependently sup-
pressed LXRa- and LXRb-dependent transcription at nanomolar
concentrations (Figures 1B and 1C) in both consensus LXRE-
and endogenous (FASN) promoter driven luciferase reporter-
assays. In addition, SR9243 potently inhibited LXR-driven
luciferase activity in cultured cancer cells (Figure 1D). SR9243
displayed high selectivity for LXR as it failed to significantly influ-
ence the activity of any other nuclear receptors (Figure S1A) at
10 mM concentration: a maximally efficacious dose (Figures
1B–1D). Time-resolved fluorescence resonance energy transfer
assays (TR-FRET) revealed that LXR interaction with the recep-
tor interaction domains from the nuclear receptor corepressor
1 (NCOR1) and nuclear receptor corepressor 2 (SMRT) was
enhanced by SR9243 (Figures 1E and 1F). Interestingly, LXRa
ligand binding domains displayed higher affinity for SMRT core-
pressor motifs compared to that of NCOR1, which suggests that
LXRa may preferentially bind a distinct subset of corepressors
compared to LXRb, which preferred NCOR1 motifs. In contrast
to the LXR agonist T0901317, SR9243 failed to enhance recruit-
ment of the LXR coactivators TRAP220/DRIP-2 (Figure 1F).
Sequential chromatin immunoprecipitation (Re-ChIP) of LXRa
or LXRb and NCoR1 (Figures 1G, 1H, and S1B–S1D) showed
that SR9243 enhanced LXR recruitment of the transcriptional
corepressor NCoR1 to the promoters of the LXR-regulated
genes SREBF1, FASN, PFK2, and GCK1 (Figures 1H, S1B, and
S1C). Interestingly, LXRa and LXRb isoforms displayed diver-
gent promoter binding characteristics in untreated and SR9243
treated cells. LXRa and LXRb were bound at the SREBPF pro-
moter in the absence of ligand treatment (Figure 1H). However,
unliganded LXRa and LXRb exclusively occupied the FASNFigure 1. SR9243 Is an LXR Inverse Agonist that Induces Corepressor
(A) Structure of SR9243.
(B) FASN promoter-driven luciferase reporter assay showing SR9243 repressio
HEK293 cells. Transfected cells were treated with 0.01–10 mM of SR9243 for 6 h
(C) LXRE-driven (3X) luciferase reporter assay showing SR9243 repression of bas
with 1 nM–10 mM SR9243 for 6 hr.
(D) LXRE-driven luciferase reporter dose-response assays in cancer cell lines ex
(E) TR-FRET assay showing the recruitment of corepressor box peptides NCoR
(F) TR-FRET assay showing relative recruitment of NCoR, SMRT, and TRAP220/D
1 mM of the LXR agonist T0901317.
(G) Diagram illustrating the Re-ChIP experiment shown in (H) PCR results of Re-Ch
corepressor recruitment at the promoters ofGCK1,PFK2, SREBF, and FASN. (C,
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent ±SEM. See also Figure Sand PFK2 promoters, respectively. Differential promoter occu-
pancy by inactive LXRa and LXRb has been shown previously
and may be responsible for divergent roles each LXR isoform
has in metabolism (Wagner et al., 2003). LXRa and b were en-
riched at FASN, SREBPF, PFK2, and GCK1 promoters upon
exposure to SR9243, but not at the GAPDH promoter, suggest-
ing that SR9243 selectively stimulated LXR binding to LXREs
(Figures 1H and S1B–S1D). Interestingly, NCoR1 was recruited
by LXRb to the SREBF, FASN, PFK2, and GCK1 promoters,
whereas LXRa interacted with NCOR1 at the PFK2 promoter
only. In tandem with our results in TR-FRET assays (Figure 1E),
this observation suggests that LXRa and LXRb isoforms differen-
tially recruit corepressors depending on the target promoter
context (Figure 1H). Alternatively, these results suggest that
LXRb may be the dominant isoform involved in mediating
SR9243-driven gene suppression. Collectively these observa-
tions demonstrate that SR9243 induces corepressor recruitment
to LXRs at target-gene promoters, leading to suppression of
gene expression.
SR9243 Reduces Cancer Cell Viability and Induces
Apoptotic Cell Death
Most cancer cells are highly dependent on the Warburg effect
and are often forced into apoptotic cell death when subjected
to glycolytic blockade. First, to determine the efficacy of
SR9243 as an anti-tumor agent, we assessed the effect of
SR9243 on cancer cell viability in a variety of cancer cell types.
SR9243 potently reduced cancer cell viability at nanomolar con-
centrations (half-maximal inhibitory concentration [IC50] 15–
104 nM) in MTT reduction assays in prostate (PC3 and DU-
145), colorectal (SW620 and HT29), and lung (HOP-62 and
NCI-H23) cancer cell lines (Table 1 and Figure 2A). Conversely,
SR9243 did not reduce the viability of non-malignant cells thatRecruitment
n of the basal activity of exogenously expressed full-length LXRa or LXRb in
r.
al activity of endogenously expressed LXRs in HEK293 cells. Cells were treated
pressing exogenous LXRa or LXRb and treated with SR9243.
and SMRT to LXRa and LXRb in response to SR9243.
RIP-2 box peptides to LXRa or LXRb LBDs in response to vehicle of SR9243 or
IP assays of LXRa or LXRb followed by NCOR1 showing SR9243 (SR)-induced
control; SR, SR9243) Representative figure of experiment repeated three times.
1.
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originate from the same organs—prostate (PZ-HPV-7), colon
(CCD-18Co), and lung (MRC-5)—which express similar levels
of LXRs (Figures 2B and S2A). The colony-forming capacity of
cancer cells was also significantly lowered by SR9243 in a
dose-dependent manner (Figure 2C). Cancer cell death
occurred as early as 12 hr following SR9243 treatment (Fig-
ure 2D), which coincided with a robust increase in caspase-
3/7 activation (Figure 2E) and induction of apoptotic cell death
(Figure 2F). LXRs have been shown to modulate cell cycle regu-
lation genes, and LXR agonists have been shown to inhibit pro-
liferation by blocking cell cycle progression (Meng et al., 2009;
Nguyen-Vu et al., 2013; Vedin et al., 2012). However, SR9243-
treated cells showed no significant changes in the expression
a number of key cell cycle arrest genes:P21, P15, P27,
MDM2, P52, and GADD45 (Figure S2B); or cell cycle progres-
sion genes: CCNE, CDC25, CCNB1, CCND1, and CCNA2 (Fig-
ure S2C), suggesting that SR9243-induced apoptotic cell death
was not due to LXR-mediated cell cycle arrest. Like the inverse
agonist SR9243, the LXR agonist (GW3965) has been shown to
inhibit cancer cell growth. However, GW3965 as well as other
LXR agonists mediate their anti-neoplastic effects via reduction
of intracellular cholesterol levels and induction of cell cycle ar-
rest (Lo Sasso et al., 2013; Nguyen-Vu et al., 2013; Vedin
et al., 2012). Co-treatment of cancer cells with GW3965 and
SR9243 shows reciprocal modulation of LXR activity (Fig-
ure S2D). In addition, GW3965 dose-dependently reduced the
toxicity of SR9243 in cancer cells, demonstrating that both
types of ligands target the LXR and modulate LXR activity in
quantifiably opposite directions (Figure S2E). This shows that
LXR agonists and inverse agonists disrupt cancer cell growth
by modulating LXR gene regulated pathways through distinct
mechanisms.
To determine whether cancer cell death and gene suppression
by SR9243 was LXR dependent, we decided to knock down the
expression of LXR in cancer cells using LXRa and b specific
siRNAs. We postulated that if the activity of SR9243 is LXR-
dependent, depleting LXR levels through siRNA knockdown
would diminish the anti-neoplastic and gene suppressive effects
of SR9243. Indeed, downregulation of LXR expression reduced
SR9243-mediated repression of LXR target genes (Figure S2F)
and rescued cancer cell viability in SR9243-treated cells (Fig-
ure 2G). Collectively, these results demonstrate that the effects
of SR9243 on cancer cell viability are LXR dependent and non-
toxic to normal cells.Figure 2. SR9243 Induces Apoptotic Cell Death in Multiple Cancer Cel
(A) MTT assay showing the viability of cancer cells from the prostate (PC3, DU-14
doses of SR9243.
(B) MTT assay of non-malignant cells from the prostate (PZ-HPV-7), colon (CCD
(C) Colony formation assay of cancer cells treated with vehicle, or 100 nM or 10
(D) Fluorescent cell viability/apoptosis assay showing the viable cells (blue) and
12 and 24 hr.
(E) Luminescence-based caspase 3/7 activity of SW620, HOP62, and DU-145 cell
for 24 hr.
(F) FACs sorting of Annexin V FITC/PI-stained SW620 cells treated with SR9243 (1
are graphically represented in lower image.
(G) MTT reduction assay showing rescue of cell viability of SW620 colon cancer
mock transfected cells. LXR expression in SW620 cells treated with LXR siRNAs
(H) MTT reduction assay showing the viability of DU-145, SW620, and HOP-62 ca
cisplatin. Experiments were repeated three times. *p < 0.05, **p < 0.01, ***p < 0.SR9243 Sensitizes Cancer Cells to Chemotherapeutic
Treatments
As SR9243 effectively reduced cancer cell viability, we investi-
gated whether SR9243 could be a complementary treatment
to cytotoxic chemotherapeutic drugs when used in combination.
SR9243 treatment profoundly enhanced the efficacy of 50-fluoro-
uracil or cisplatin in all cancer cells tested (Figure 2H). This
collectively highlights that SR9243 could be a viable cancer
treatment approach either administered alone or as a part of
combination therapy.
SR9243 Disrupts the Warburg Effect in Cancer Cells
LXR directly regulates multiple components of the glycolysis
pathway (Figure 3A). Considering the potent selective effect
SR9243 has on cancer cell viability, we sought to investigate
the effects SR923 on LXR-regulated gene expression specif-
ically in cancer cells. First, we assessed whether SR9243 sup-
pressed expression of enzymes that are known to mediate the
Warburg effect in cancer cells. Cells treated with SR9243
showed significantly suppressed glycolytic gene expression
(GCK1, PFK2, PFK1, and LDH) (Figures 3B and S3A). To truly
inhibit the Warburg effect in cancer cells, SR9243 must reduce
the intracellular concentrations of glycolytic metabolites.
Biochemical assessment and gas chromatography/mass spec-
trometry (GC/MS) analysis revealed that intracellular levels of py-
ruvate, hexose phosphates, and lactate were significantly
reduced by SR9243 (Figures 3C and 3D). Notably, SR9243
reduced the levels of lactate and pyruvate to that of cells treated
with 2-deoxyglucose (Figure 3D), a potent hexokinase inhibitor
that has reached phase II clinical cancer-drug trials (Mohanti
et al., 1996). These results suggest that SR9243mediated a sub-
stantial decrease in glycolytic enzyme expression that signifi-
cantly affected glycolytic output in cancer cells.
SR9243 is Non-toxic to Normal Cells
Normal cells require glycolysis for energy production. Therefore
glycolytic enzyme inhibitors often produce undesired toxic ef-
fects in non-tumor tissues because they also inadvertently
disrupt the activity of glycolysis enzymes required for sustaining
respiration in normal cells. Whether SR9243 truly had a selec-
tively pernicious effect on the elevated rate of glycolysis in can-
cer cells was uncertain. SR9243 did not suppress glycolytic gene
expression or glycolysis metabolite concentrations in non-malig-
nant cells (Figures S3B and S3C). To further investigate thisl Types in an LXR-Dependent Manner
5), colon (SW620, HT-29), and lung (HOP-62, NCI-H23) treated with increasing
-18Co), and lung (MRC5) treated with SR9243.
mM SR9243.
or the apoptotic cells (green) from SW620 cells treated with 1 mM SR9243 for
s treated with vehicle, 1 mMSR9243, and or the caspase inhibitor (Z-VAD-FMK)
00 nM) for 24 hr. The percentage of apoptotic, necrotic and live cell populations
cells transfected with LXRa and LXRb-specific siRNAs compared to control or
(right).
ncer cells in response to SR9243 alone or in combination with 50-fluorouracil or
001. Error bars represent ±SEM. See also Figure S2.
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Figure 3. SR9243 Inhibits Glycolytic Lipogenic Enzymes in Cancer Cells
(A) Schematic showing glycolysis genes regulated by LXRs and associated metabolites. Gene names outlined in boxes are directly regulated by LXRs.
(B) RT-PCR showing expression of LXR-regulated glycolysis genes GCK1, PFK1, and PFK2 after 6 hr treatment with SR9243 (10 mM).
(C) Biochemically determined cellular levels of lactate and pyruvate in HOP-62 cancer cells treated with SR9243 for 24 hr.
(D) GC/MS determined levels of lactate and hexose phosphates in PC3 and HOP62 cancer cells.
(legend continued on next page)
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selective effect of SR9243 on cancer cell glycolytic output, the
extracellular acidification rate (ECAR) and oxygen consumption
rate (OCR) of cancer cells and non-malignant cells treated with
SR9243 was measured. As expected, due to theWarburg effect,
the cancer cells assayed displayed a much higher ECAR
compared to normal cells. Interestingly, SR9243 treatment
selectively reduced the relatively high glycolytic output of cancer
cells to levels comparable to that of non-malignant cells (Fig-
ure 3E). Notably, SR9243 did not significantly suppress glycol-
ysis in non-malignant cells (Figure 3E). In addition, SR9243 failed
to significantly disrupt OCR in both cancer cells and non-malig-
nant cells (Figure 3E, bottom). These results were consistent with
the selective effect SR9243 had on cancer cell viability
compared to the innocuous effect SR9243 had on non-malignant
cells (Figures 2A and 2B). Further, these observations suggest
that SR9243-mediated glycolytic gene suppression preferen-
tially disrupts elevated glycolytic output in cancer cells without
adversely affecting respiration in normal cells.
SR9243 Suppresses Lipogenesis Gene Expression
and Lipid Production in Cancer Cells
Similar to LXR-regulated glycolysis genes, SR9243 repressed
the lipogenesis genes directly regulated by LXR: FASN,
SREBP1-c, and SCD1 (Figures 3F and 3G). SR9243 substan-
tially disrupted lipogenic gene expression in all the cancer cell
lines tested (Figure 3F). In particular, NCI-H23 and DU-145 cells
showed potent reduction in FASN, SREBP1c, and SCD1
expression in contrast to the modest effect on glycolysis
enzyme expression observed in these cell lines (Figures 3B
and 3F; Figure S3A). SR9243 reduced the expression of the lipo-
genic genes FASN and SCD1 (Figure S3D) and intriguingly did
not inhibit the expression of SREBP1c in normal cell lines in
contrast to the profound effect on SREBP1c expression
observed in cancer cells (Figures S3D and 3G). SR9243 reduced
expression of the cholesterol transport gene ABCA1 in both
normal and malignant cell lines (Figures S3E and S3F), which
suggested that SR9243 selective activity was not due to
enhanced cholesterol export. Within cancer cells the intracel-
lular levels of major end products of lipogenesis—palmitate,
stearate, palmitoleate, and myristoleate (Figure 3H)—were
significantly reduced by SR9243. Select fatty acids like oleate
have been shown to rescue cell viability in cancer cells treated
with lipogenesis enzyme-specific inhibitors (e.g., TOFA), which
target upstream lipogenesis enzymes like SCD1 (Mason et al.,
2012). Interestingly culture media supplemented with individual
fatty acids, such as oleate, stearate, and palmitate, could not
significantly rescue the viability of SR9243-treated cancer cells
(Figure S3G). Further, combined supplementation of cancer
cell media with oleate, stearate, and palmitate in combination(E) Relative glycolytic rate (ECAR/OCR) and oxygen consumption rate (OCR) of H
cells (MRC5) treated with SR9243 (100 nM or 10 mM). Cells were assessed for ex
analyzer.
(F) Schematic showing the lipogenesis genes regulated by LXR and their cognate
lipogenesis genes SREBP1c, FASN, and SCD1 in cancer cells treated with SR92
(G andH) (G) GC/MS showing cellular levels of the long-chain fatty acids palmitole
acids (2-hydroxy-palmitate and 2-hydroxy-stearate) in SW620 and HOP-62 cells
(I) MTT assay of DU-145 and SW620 cells treated with increasing amounts of SR9
oleate, palmitate, and stearate) for 96 hr. Data were analyzed usingWelch’s t tests
Error bars represent ±SEM. See also Figure S3.completely rescued cancer cell viability in cancer cells (Fig-
ure 3I). This suggests that multiple points in the lipogenesis
pathway are targeted by SR9243 treatment. Fatty acid supple-
mentation also rescued the viability of SW620 cells in which
glycolysis was substantially disrupted (Figure 3I). This observa-
tion is supported by previous studies that have similarly shown
that lipid uptake by cancer cells can temporarily sustain cancer
cell viability when energy substrates are limited (Carracedo
et al., 2013; Dang et al., 1997). As discussed previously, non-
malignant cells are not typically dependent on lipogenesis
for normal function. Therefore, these findings suggest that
SR9243 is a potent inhibitor of lipogenic gene expression that
selectively kills cancer cells by depleting intracellular lipids.
Based on these results, it is predicted therefore that SR9243
should display therapeutic activity in both highly glycolytic and
or lipogenic tumor cell subtypes.
SR9243 Inhibits LXR-Dependent Gene Expression
and Tumor Growth In Vivo
To examine whether SR9243 could elicit a similarly potent down-
regulation of LXR activity in vivo, we first tested the ability of
SR9243 to inhibit lipogenesis in mice. To accomplish this, we
test the effects of SR9243 on Ob/Ob mice fed a high-fat diet,
an established mouse model of elevated lipogenic signaling
and enzyme expression. In this mouse model, SR9243 was
able to suppress hepatic steatosis in vivo (Figure S4A). We then
went on to test the anti-cancer properties of SR9243 in xenograft
cancer models to determine if SR9243 could impede tumor
growth in vivo. Colon cancer tumor xenograft growth (SW620)
was substantially reduced by SR9243 treatment (Figure 4A) in a
dose-dependent manner. A number of lipogenesis inhibitors
have been tested in vivo that promote rapid weight loss and
loss of appetite, making them unviable clinical therapies (Clegg
et al., 2002; Tu et al., 2005). However, SR9243-treated tumor-
bearingmice did not display anyweight loss (Figure 4B). Notably,
SR9243 treatment did not significantly modulate LXR receptor
levels (Figures S4B and S4C). SR9243 also significantly and
dose-dependently reduced glycolytic (GCK1, PFK2, PFK1,
and LDH; Figures 4C and 4E) and lipogenic (SCD1, FASN, and
SREBP1c) enzymeexpression in colon tumor xenografts (Figures
4D and 4E). In addition, GC/MS analysis showed that treated
mice had reduced levels of the key metabolite markers of glycol-
ysis (pyruvate and glycerate; Figure 4F) and a substantial reduc-
tion in total tumor lipid content (Figure 4G). In situ TUNEL assays
also revealed that SR9243-treated tumors contained significantly
more apoptotic cells (Figure 4H). These results indicate that
SR9243 was able to profoundly inhibit tumor glycolysis, lipogen-
esis, and induce apoptotic cancer cell death without promoting
weight loss in vivo. Further, these results suggest that LXROP-62 lung cancer cells or the corresponding non-tumorigenic lung epithelial
tracellular acidification rate and OCR using the Seahorse XF extracellular flux
substrates and products. RT-PCR showing expression profile of LXR-regulated
43 (10 mM) for 6 hr.
ate andmyristoleate in SR9243 treated cancer cells and (H) the short-chain fatty
treated with SR9243. Samples were normalized by total protein concentration.
243 in LFM (lipid-free media) or positive lipid media (supplemented with 25 nM
and/or Wilcoxon’s rank sum tests. *p < 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. SR9243 Reduces Tumor Growth, Glycolytic and Lipogenic Enzyme Expression in Tumors In Vivo
(A) Volume of SW620 colon cancer xenografts in athymic mice treated with vehicle (n = 9), 30 mg/kg (n = 9), or 60 mg/kg (n = 9) SR9243.
(B) Total body weight of mice from (A).
(C and D) RT-PCR analysis of the (C) glycolytic genesGCK1,PFK1, andPFK2 and (D) the lipogenesis genes SREBP1c andSCD1 in tumors of mice treatedwith 30
and 60 mg/kg SR9243. RT-PCR data were analyzed using Student’s t test. *p < 0.05.
(legend continued on next page)
50 Cancer Cell 28, 42–56, July 13, 2015 ª2015 Elsevier Inc.
inverse agonists unlike previous lipogenesis inhibitors may not
adversely affect lipid homeostasis or food intake.
SR9243-Mediated Lipogenic Enzyme Expression Is
Sufficient for Inhibition of Tumor Growth In Vivo
As mentioned earlier, cancer cells within the tumor microenvi-
ronment can display metabolic plasticity and temporarily
reduced dependence on glycolytic metabolite production de-
pending on pH and oxygen availability. In tumor cells, glycolytic
metabolites are funneled into lipogenic pathways where they are
converted into short-, medium-, and long-chain fatty acids that
can be incorporated into plasma cell and organelle membranes
or used as signaling molecules. Unlike glycolysis, tumor lipogen-
esis is less dependent on tumor microenvironment changes.
Therefore, effectively blocking both glycolytic and lipogenic
pathways exploited by cancer cells may be especially useful
for targeting tumor cell types with distinct metabolic profiles.
We observed that SR9243 dually inhibited glycolytic and lipo-
genic enzyme expression in vitro and in vivo. Interestingly,
SR9243 failed to reduce the expression of multiple glycolytic en-
zymes. Specifically in DU-145 andNCI-H23 cells (Figures 3B and
S3A), only LDH and PFK2 expression were modestly reduced.
These mild effects on glycolysis gene expression did not fully
correlate with the significant disruption of cell growth observed
in these cell lines (Figure 2A). Considering this, we tested
whether SR9243 could similarly ablate DU-145 tumor xenograft
growth in vivo without substantially inhibiting glycolytic gene
expression. SR9243 potently reduced DU-145 tumor growth
(Figure 5A). As observed in colon cancer tumor xenograft
models, SR9243 did not cause any reduction in total bodyweight
(Figure 5B). In these tumors SREBP-1c, SCD1, and FASN
expression was markedly suppressed (Figures 5C–5E). Consis-
tent with our observations in vitro, SR9243 did not reduce the
expression of GCK1, PFK2, or PFK1 (Figure 5F). Interestingly,
SR9243 also had no effect on LDH expression levels in DU-
145 tumors as observed in cultured cells (Figures 5F and S3A).
In addition, SR9243 did not influence pyruvate or lactic acid
levels within tumors (Figure S5B). However, SR9243 significantly
reduced DU-145 fatty acid metabolite content (Figure S5B).
Therefore, these results demonstrated that SR9243 inhibits tu-
mor growth without profoundly repressing glycolytic gene
expression. This implies that because of its dual-pathway activ-
ity, SR9243 should have efficacy in cancer cells that display var-
iable glycolytic activity within the metabolically heterogeneous
tumor microenvironment.
SR9243 Blocks Tumor Growth without Causing Immune
or Hepatic Toxicity In Vivo
We have shown previously that long-term treatment with an LXR
inverse agonist did not enhance inflammatory cytokines in the
liver and inhibited liver inflammation in amousemodel of fatty liver
disease (Griffett et al., 2013).Weassessedwhetheradministration
of SR9243 to immune competent (C57BL6J) tumor-bearing mice(E) Immunoblot showing expression levels of SREBP1c, FASN, SCD1, GCK1, an
(F) GC/MS determined concentration of pyruvate and glycerate in SW620 xenogr
t tests and/or Wilcoxon’s rank sum tests. *p < 0.05. Error bars represent ±SEM.
(G) Oil red O staining showing lipid content of SW620 tumors in mice treated wit
(H) Fluorescence based in situ TUNEL assay showing apoptotic cells in tumors frostimulated inflammation or hepatic toxicity. Similar to the effect of
SR9243 on tumor growth in nude mice, SR9243 profoundly in-
hibited Lewis lung carcinoma (LLC1) tumor growth in C57BL6J
mice (Figure 6A). LXR-regulated lipogenic and glycolytic gene
expression was also substantially reduced (Figures 6B and 6C)
without promoting weight loss (Figure 6D). Biochemical profiling
of mouse plasma revealed that plasma glucose levels was
unchanged (Figure 6E). Interestingly, SR9243 also significantly
increased Tnfa levels within tumors, without elevating expression
levels of Tnfa, IL6, or IL5 in the liver (Figures 6F, S6A, and S6B).
Thus, immune activation in SR9243-treated mice was isolated
to tumors and relatively absent in normal tissue. Previous studies
have shown that tumors secrete LXR agonists that suppress den-
dritic cell activation and promote immune silencing or tumor
‘‘masking.’’ This tumor-specific elevation of Tnfa suggests that
SR9243 may be inducing tumor ‘‘unmasking’’ in treated mice.
SR9243 also reduced total cholesterol and significantly reduced
both low-density and high-density lipoprotein (LDL and HDL)
plasma levels (Figure 6G) in SR9243-treated mice, consistent
with previous observations in mice treated with LXR inverse ago-
nists (Griffett et al., 2013). SR9243 treatments mediated these ef-
fectswithout inducing liver toxicitymarkers (Figure 6H). Together,
these results indicate that SR9243 inhibits tumor lipogenesis
and glycolysis and induces apoptotic cancer cell death with no
evidence of hepatic toxicity or pro-inflammatory effects.
DISCUSSION
The metabolic profiles of cancer cells are distinct from those of
normal cells due to the Warburg effect and lipogenesis. These
are key metabolic pathways that drive cancer progression,
growth, survival, immune evasion, resistance to treatment, and
disease recurrence (Fritz et al., 2010; Huang et al., 2012; Vander
Heiden et al., 2009; Yeung et al., 2008). Therefore, by targeting
glycolysis and lipogenesis, a broad range of cancers can be
treated. This work establishes that targeted repression of glycol-
ysis and lipogenesis can be achieved via suppression of LXR
target-gene expression. Notably, LXR signaling has not been
shown to initiate the Warburg effect in tumor cells. LXRs, how-
ever, directly regulate a number of key glycolytic and lipogenic
enzymes that facilitate theWarburg effect and tumor lipogenesis,
respectively. Therefore, we used an LXR inverse agonist to ‘‘hi-
jack’’ the unliganded LXR and promote corepressor recruitment
and formation of repressor complexes at the promoters of LXR-
regulated genes. This approach reduced LXR transcriptional ac-
tivity to below basal levels and therefore suppressed lipogenic
and glycolytic gene expression, thereby inhibiting tumor growth.
The past few decades the Warburg effect and lipogenesis has
been extensively studied with the goal of identifying targeted
therapies that are selectively cytotoxic to cancer cells. A number
of enzyme-specific inhibitors that target glycolysis enzymes and
lipogenesis enzymes have been tested in rodent cancer models.
Despite these efforts, no clinically viable cancer metabolismd PFK2 protein in SW620 tumors treated with 30 or 60 mg/kg SR9243.
afts in mice treated with 30 mg/kg SR9243. Data were analyzed using Welch’s
h 60 mg/kg SR9243 or vehicle.
m mice treated with SR9243 (60 mg/kg) or vehicle control. See also Figure S4.
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Figure 5. SR9243 Treatment Inhibits Lipogenic Enzyme Expression to Suppress Tumor Growth
(A) Volume of prostate cancer (DU-145)-xenografts in nude mice treated with 60 mg/kg SR9243 (n = 8) or vehicle (n = 7).
(B) Total body weight of mice treated in (A).
(legend continued on next page)
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Figure 6. SR9243 Inhibits Tumor Growth and Lipogenesis without Hepatotoxicity or Inflammation
(A) Volume of mouse Lewis lung carcinoma (LLC1) syngeneic tumors implanted in C57BL6/J mice treated with vehicle (n = 8) or 60 mg/kg SR9243 (n = 8).
(B and C) RT-PCR analysis of (B) Srebp1c, Fasn, and (C) Pfk2 expression in tumors from mice treated with SR9243 or vehicle.
(D) Total body weight of tumor-bearing mice treated with SR9243.
(E) Serological analysis of blood glucose levels in vehicle and SR9243-treated mice.
(F) RT-PCR analysis showing expression of the cytokine Tnfa in livers and LLC1 tumors of C57BL6J mice treated with SR9243. See also Figure S5.
(G) Plasma levels of total cholesterol (CHOL), triglycerides (TRIG), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in vehicle and SR9243
(60 mg//kg)-treated mice.
(H) Plasma levels of the liver transaminases aspartate transaminase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) as well as total al-
bumin (ALB) in vehicle and SR9243-treated tumor-bearing mice. All RT-PCR and serological data were analyzed using a two-tailed t test followed by Bonferroni
post-test. *p < 0.05. Error bars represent ±SEM. See also Figure S6.inhibitors for solid tumors have been forthcoming and only one
glycolysis inhibitor, 2-deoxy-glucose, has made it to phase II
clinical trials (Mohanti et al., 1996). The challenges of using
enzyme-specific glycolysis and lipogenesis inhibitors for treating
solid tumors may be inherently flawed due to their mode of ac-
tion. Ideally, to effectively inhibit glycolytic and lipogenic enzyme
activity, enzyme inhibitors must block the catalytic activity of
overexpressed enzymes in tumor tissues. Cancer cells have a
surplus pool of catalytically active enzyme molecules relative
to normal cells. Therefore, to effectively disrupt tumor meta-
bolism, enzyme-specific inhibitors are expected to selectively
target and disrupt metabolic processes in relatively more
metabolically active tumor cells while sparing less active non-
malignant cells. Therefore, the dosage of enzyme inhibitor
required to obtain the desired therapeutic effects in vivo also
adversely affects the metabolic functions of normal cells. These(C) RT-PCR showing expression of SREBP1c and SCD1 in tumors from mice trea
by Bonferroni post-test. *p < 0.05. Error bars represent ±SEM).
(D) Immunoblot showing protein expression of SREBP1c and SCD1 in control an
(E) Fluorescence-based immunohistochemistry SREBP1c and FASN expression
(F) RT-PCR showing expression of PFK1, PFK2, GCK1, and LDH in tumors treated
Bonferroni post-test. *p < 0.05.
(G) Immunoblot showing protein expression of SREBP1c and SCD1 in control and
vehicle. See also Figure S5.limitations restrict the ‘‘therapeutic window’’ significantly for
enzyme-specific inhibitors as clinical treatments for solid
tumors.
Interestingly, in this study we observed that the effect of
SR9243 on cancer cell glycolytic gene expression was not
conserved across all cell types. The prostate cancer cell line
DU-145 and non-small cell lung carcinoma cell line NCI-H23
both displayed limited repression of glycolytic genes in response
to SR9243 but were highly responsive to SR9243 treatment. The
underlying mechanism responsible for the differential effect
SR9243 had on glycolysis gene expression in these cell types
may be due to a number of factors. These cancer cells
may exhibit cell type specific deregulation of glycolytic gene
expression that limit LXR-mediated gene repression. Despite
directly regulating the expression of key glycolytic genes, LXRs
have a shared role in glycolytic gene regulation along withted with SR9243 or vehicle. Data were analyzed using Student’s t test followed
d SR9243-treated tumors.
in tumors from vehicle and SR9243-treated mice.
with SR9243 or control. Data were analyzed using Student’s t test followed by
SR9243-treated tumors and SCD1 in tumors frommice treated with SR9243 or
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other nuclear receptors (e.g., PPARs and TRa) and oncogenes
such (e.g., HIF and MYC). Therefore, resistance to LXR-medi-
ated glycolytic disruption could be due to metabolic compensa-
tion driven by other receptor signaling pathways or oncogenes.
Interestingly, NCI-H23 and DU-145 cells lack functional LKB1,
a tumor suppressor that inhibits the Warburg effect through
regulation of AMPK and downstream regulation of glycolysis
enzyme expression. However, SR9243 was able to repress
glycolysis gene expression in cancer cells that expressedmutant
LKB1 (data not shown). This suggests that the underlying mech-
anisms for resistance to glycolysis gene repression may bemore
complex. Nonetheless, identification of the factors that may
contribute to resistance to SR9243 mediated repression of
glycolytic gene expression should be the subject of further in-
quiry. Our investigation did demonstrate, however, that LXR
repression of lipogenic gene expression was sufficient to induce
tumor cell death.
The favorable safety profile and lack of toxicity SR9243 dis-
played in non-malignant cells and tissues may be inherent to
the mechanism of action of LXR-mediated glycolytic and lipo-
genic gene suppression. Our observations suggest that recep-
tor-mediated downregulation of glycolytic and lipogenic enzyme
expression using an LXR inverse agonist may be a more selec-
tive therapeutic strategy for disrupting the Warburg effect and
lipogenesis than targeted enzyme inhibition. Our observations
suggest that downregulation of key enzymes that drive the War-
burg effect and/or lipogenesis in cancer cells produces a meta-
bolic environment that is unable to support cancer cell growth
but sufficient for the function of normal cells. Therefore, we pro-
pose that SR9243 facilitates the reprogramming of cancer cell
metabolism to ‘‘normal’’ levels that cannot sustain cancer cell
growth. SR9243 therefore is able to promote apoptotic cancer
cell death without adversely affecting non-malignant cells. How-
ever, our observations notwithstanding, the underlying mecha-
nism driving SR9243 cancer cell selectivity and low toxicity is still
uncertain and should be the subject of further investigation.
A number of recently published studies suggest that LXR acti-
vation may be a key pathway mediating cancer cell immune
evasion through silencing of dendritic cell activity (Russo,
2011; Villablanca et al., 2010). In our investigations, we observed
that SR9243 specifically induced substantial inflammation in the
tumors without causing systemic inflammation. These observa-
tionsmay be due to enhanced immune cell infiltration into tumors
due to SR9243 treatment. Therefore, SR9243 may mediate tu-
mor ‘‘unmasking’’ via downregulation of the immune-suppres-
sive effects of LXR ligands within the tumor microenvironment.
Preliminary experiments have suggested that SR9243 is able
to induce dendritic cell activity that is suppressed by tumor-pro-
duced LXR ligands (data not shown). However, whether SR9243
can promote immune-mediated tumor clearance is unclear and
should be the subject of further investigation and may highlight
a promising avenue of exploration into the role of LXR as a ther-
apeutic cancer target.EXPERIMENTAL PROCEDURES
Animals
This study was carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes54 Cancer Cell 28, 42–56, July 13, 2015 ª2015 Elsevier Inc.of Health. The protocol was approved by Institutional Animal Care and Use
Committee of the Saint Louis University School of Medicine. Nu/Nu (Charles
River) C57BL/6J andOb/Obmice (Jackson Laboratories) were housed in ster-
ile ventilated cages, fed a standard diet unless otherwise specified, and pro-
vided water ad libitum. Mice were killed using CO2 followed by cervical
dislocation.
Synthesis and Purification of SR9243
Detailed synthesis of SR9243 can be found in the Supplemental Experimental
Procedures.
Chromatin Immunoprecipitation Assay
HepG2 were treated with DMSO vehicle or SR9243 (10 mM) for 48 hr fixed us-
ing Formaldehyde (1%) for 10 min. Sequential chromatin immunoprecipitation
(Re-ChIP) was performed using the Re-ChIP IT kit (Active Motif) as per manu-
facturer’s instruction.
Tumor Xenograft Experiments
Cancer cell lines were harvested using Trypsin/EDTAwashedwith PBS and re-
suspended in PBS containingMatrigel. SW620 (53 106 cells), DU-145 (53 106
cells), and LLC cells (13 106) cells were implanted subcutaneously in the lower
right flank of 5-week-oldNu/Nu (Charles River) or C57BL6J (LLC1) mice. All tu-
mor xenografts were allowed to reach a volume of 100 mm3 before treatment
commenced.
Statistical Analysis
All data were subjected to either ANOVAor t tests where specifiedwith Tukey’s
post hoc test. *p < 0.05 is considered statistically significant. *p < 0.05, **p <
0.01 ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2015.05.007.
Received: November 12, 2014
Revised: March 27, 2015
Accepted: May 12, 2015
Published: June 25, 2015
REFERENCES
Baranowski, M. (2008). Biological role of liver X receptors. J. Physiol.
Pharmacol. 59 (Suppl 7 ), 31–55.
Beyea, M.M., Heslop, C.L., Sawyez, C.G., Edwards, J.Y., Markle, J.G., Hegele,
R.A., and Huff, M.W. (2007). Selective up-regulation of LXR-regulated genes
ABCA1, ABCG1, and APOE in macrophages through increased endogenous
synthesis of 24(S),25-epoxycholesterol. J. Biol. Chem. 282, 5207–5216.
Blancher, C., and Harris, A.L. (1998). The molecular basis of the hypoxia
response pathway: tumour hypoxia as a therapy target. Cancer Metastasis
Rev. 17, 187–194.
Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R.G.,
Chiavarina, B., Frank, P.G., Flomenberg, N., Howell, A., Martinez-Outschoorn,
U.E., et al. (2010). Ketones and lactate ‘‘fuel’’ tumor growth and metastasis:
Evidence that epithelial cancer cells use oxidative mitochondrial metabolism.
Cell Cycle 9, 3506–3514.
Carracedo, A., Cantley, L.C., and Pandolfi, P.P. (2013). Cancer metabolism:
fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227–232.
Chaje`s, V., Cambot, M., Moreau, K., Lenoir, G.M., and Joulin, V. (2006). Acetyl-
CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res.
66, 5287–5294.
Chuu, C.P., and Lin, H.P. (2010). Antiproliferative effect of LXR agonists
T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines.
Anticancer Res. 30, 3643–3648.
Clegg, D.J., Wortman, M.D., Benoit, S.C., McOsker, C.C., and Seeley, R.J.
(2002). Comparison of central and peripheral administration of C75 on food
intake, body weight, and conditioned taste aversion. Diabetes 51, 3196–3201.
Dang, C.V. (2007). The interplay between MYC and HIF in the Warburg effect.
Ernst Schering Found Symp Proc. 35–53.
Dang, C.V., Lewis, B.C., Dolde, C., Dang, G., and Shim, H. (1997). Oncogenes
in tumor metabolism, tumorigenesis, and apoptosis. J. Bioenerg. Biomembr.
29, 345–354.
Darimont, C., Avanti, O., Zbinden, I., Leone-Vautravers, P., Mansourian, R.,
Giusti, V., and Mace´, K. (2006). Liver X receptor preferentially activates de
novo lipogenesis in human preadipocytes. Biochimie 88, 309–318.
DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008).
The biology of cancer: metabolic reprogramming fuels cell growth and prolif-
eration. Cell Metab. 7, 11–20.
Fritz, V., Benfodda, Z., Rodier, G., Henriquet, C., Iborra, F., Avance`s, C., Allory,
Y., de la Taille, A., Culine, S., Blancou, H., et al. (2010). Abrogation of de novo
lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic
signaling and blocks prostate cancer progression inmice.Mol. Cancer Ther. 9,
1740–1754.
Furuta, E., Okuda, H., Kobayashi, A., and Watabe, K. (2010). Metabolic genes
in cancer: their roles in tumor progression and clinical implications. Biochim.
Biophys. Acta 1805, 141–152.
Grefhorst, A., Elzinga, B.M., Voshol, P.J., Plo¨sch, T., Kok, T., Bloks, V.W., van
der Sluijs, F.H., Havekes, L.M., Romijn, J.A., Verkade, H.J., and Kuipers, F.
(2002). Stimulation of lipogenesis by pharmacological activation of the liver X
receptor leads to production of large, triglyceride-rich very low density lipopro-
tein particles. J. Biol. Chem. 277, 34182–34190.
Griffett, K., Solt, L.A., El-Gendy, Bel.-D., Kamenecka, T.M., and Burris, T.P.
(2013). A liver-selective LXR inverse agonist that suppresses hepatic steatosis.
ACS Chem. Biol. 8, 559–567.
Huang, W.C., Li, X., Liu, J., Lin, J., and Chung, L.W. (2012). Activation of
androgen receptor, lipogenesis, and oxidative stress converged by
SREBP-1 is responsible for regulating growth and progression of prostate can-
cer cells. Mol. Cancer Res. 10, 133–142.
Jamroz-Wisniewska, A., Wo´jcicka, G., Horoszewicz, K., and Be1towski, J.
(2007). Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology,
and therapeutic implications. Postepy Hig Med Dosw (Online) 61, 760–785.
Joseph, S.B., Laffitte, B.A., Patel, P.H., Watson, M.A., Matsukuma, K.E.,
Walczak, R., Collins, J.L., Osborne, T.F., and Tontonoz, P. (2002). Direct and
indirect mechanisms for regulation of fatty acid synthase gene expression
by liver X receptors. J. Biol. Chem. 277, 11019–11025.
Jung, S.Y., Song, H.S., Park, S.Y., Chung, S.H., and Kim, Y.J. (2011). Pyruvate
promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression.
Int. J. Oncol. 38, 571–576.
Kim, T.H., Kim, H., Park, J.M., Im, S.S., Bae, J.S., Kim, M.Y., Yoon, H.G., Cha,
J.Y., Kim, K.S., and Ahn, Y.H. (2009). Interrelationship between liver X receptor
alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-
activated receptor gamma, and small heterodimer partner in the transcrip-
tional regulation of glucokinase gene expression in liver. J. Biol. Chem. 284,
15071–15083.
Koshiji, M., and Huang, L.E. (2004). Dynamic balancing of the dual nature of
HIF-1alpha for cell survival. Cell Cycle 3, 853–854.
Laffitte, B.A., Chao, L.C., Li, J., Walczak, R., Hummasti, S., Joseph, S.B.,
Castrillo, A., Wilpitz, D.C., Mangelsdorf, D.J., Collins, J.L., et al. (2003).
Activation of liver X receptor improves glucose tolerance through coordinate
regulation of glucose metabolism in liver and adipose tissue. Proc. Natl.
Acad. Sci. USA 100, 5419–5424.
Lo Sasso, G., Bovenga, F., Murzilli, S., Salvatore, L., Di Tullio, G., Martelli, N.,
D’Orazio, A., Rainaldi, S., Vacca, M., Mangia, A., et al. (2013). Liver X receptors
inhibit proliferation of human colorectal cancer cells and growth of intestinal tu-
mors in mice. Gastroenterology 144, 1497–1507.
Lu, C.W., Lin, S.C., Chen, K.F., Lai, Y.Y., and Tsai, S.J. (2008). Induction of py-
ruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes
metabolic switch and drug resistance. J. Biol. Chem. 283, 28106–28114.Martinez-Outschoorn, U.E., Prisco, M., Ertel, A., Tsirigos, A., Lin, Z., Pavlides,
S., Wang, C., Flomenberg, N., Knudsen, E.S., Howell, A., et al. (2011). Ketones
and lactate increase cancer cell ‘‘stemness,’’ driving recurrence, metastasis
and poor clinical outcome in breast cancer: achieving personalized medicine
via Metabolo-Genomics. Cell Cycle 10, 1271–1286.
Mason, P., Liang, B., Li, L., Fremgen, T., Murphy, E., Quinn, A., Madden, S.L.,
Biemann, H.P., Wang, B., Cohen, A., et al. (2012). SCD1 inhibition causes can-
cer cell death by depleting mono-unsaturated fatty acids. PLoS ONE 7,
e33823.
Meng, Z.X., Nie, J., Ling, J.J., Sun, J.X., Zhu, Y.X., Gao, L., Lv, J.H., Zhu, D.Y.,
Sun, Y.J., and Han, X. (2009). Activation of liver X receptors inhibits pancreatic
islet beta cell proliferation through cell cycle arrest. Diabetologia 52, 125–135.
Miller, D.H., Fischer, A.K., Chu, K.F., Burr, R., Hillenmeyer, S., Brard, L., and
Brodsky, A.S. (2011). T0901317 inhibits cisplatin-induced apoptosis in ovarian
cancer cells [corrected]. Int. J. Gynecol. Cancer 21, 1350–1356.
Mohanti, B.K., Rath, G.K., Anantha, N., Kannan, V., Das, B.S., Chandramouli,
B.A., Banerjee, A.K., Das, S., Jena, A., Ravichandran, R., et al. (1996).
Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical tri-
als on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 35, 103–111.
Nguyen-Vu, T., Vedin, L.L., Liu, K., Jonsson, P., Lin, J.Z., Candelaria, N.R.,
Candelaria, L.P., Addanki, S., Williams, C., Gustafsson, J.A., et al. (2013).
Liver 3 receptor ligands disrupt breast cancer cell proliferation through an
E2F-mediated mechanism. Breast Cancer Res. 15, R51.
Notarnicola, M., Altomare, D.F., Calvani, M., Orlando, A., Bifulco, M.,
D’Attoma, B., and Caruso, M.G. (2006). Fatty acid synthase hyperactivation
in human colorectal cancer: relationship with tumor side and sex. Oncology
71, 327–332.
Notarnicola, M., Tutino, V., Calvani, M., Lorusso, D., Guerra, V., and Caruso,
M.G. (2012). Serum levels of fatty acid synthase in colorectal cancer patients
are associated with tumor stage. J Gastrointest Cancer 43, 508–511.
Ogino, S., Shima, K., Nosho, K., Irahara, N., Baba, Y., Wolpin, B.M.,
Giovannucci, E.L., Meyerhardt, J.A., and Fuchs, C.S. (2009). A cohort study
of p27 localization in colon cancer, body mass index, and patient survival.
Cancer Epidemiol. Biomarkers Prev. 18, 1849–1858.
Pelicano, H., Martin, D.S., Xu, R.H., and Huang, P. (2006). Glycolysis inhibition
for anticancer treatment. Oncogene 25, 4633–4646.
Phan, L.M., Yeung, S.C., and Lee, M.H. (2014). Cancer metabolic reprogram-
ming: importance, main features, and potentials for precise targeted anti-can-
cer therapies. Cancer Biol. Med. 11, 1–19.
Phelan, C.A., Weaver, J.M., Steger, D.J., Joshi, S., Maslany, J.T., Collins, J.L.,
Zuercher, W.J., Willson, T.M., Walker, M., Jaye, M., and Lazar, M.A. (2008).
Selective partial agonism of liver X receptor alpha is related to differential core-
pressor recruitment. Mol. Endocrinol. 22, 2241–2249.
Rough, J.J., Monroy, M.A., Yerrum, S., and Daly, J.M. (2010). Anti-proliferative
effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res 3, 13.
Russo, V. (2011). Metabolism, LXR/LXR ligands, and tumor immune escape.
J. Leukoc. Biol. 90, 673–679.
Scaglia, N., Chisholm, J.W., and Igal, R.A. (2009). Inhibition of stearoylCoA de-
saturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in
cancer cells: role of AMPK. PLoS ONE 4, e6812.
Tu, Y., Thupari, J.N., Kim, E.K., Pinn, M.L., Moran, T.H., Ronnett, G.V., and
Kuhajda, F.P. (2005). C75 alters central and peripheral gene expression to
reduce food intake and increase energy expenditure. Endocrinology 146,
486–493.
Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009).
Understanding the Warburg effect: the metabolic requirements of cell prolifer-
ation. Science 324, 1029–1033.
Vedin, L.L., Gustafsson, J.A., and Steffensen, K.R. (2012). The oxysterol re-
ceptors LXRalpha and LXRbeta suppress proliferation in the colon. Mol.
Carcinog.
Viennois, E., Mouzat, K., Dufour, J., Morel, L., Lobaccaro, J.M., and Baron, S.
(2012). Selective liver X receptor modulators (SLiMs): what use in human
health? Mol. Cell. Endocrinol. 351, 129–141.Cancer Cell 28, 42–56, July 13, 2015 ª2015 Elsevier Inc. 55
Villablanca, E.J., Raccosta, L., Zhou, D., Fontana, R., Maggioni, D., Negro, A.,
Sanvito, F., Ponzoni, M., Valentinis, B., Bregni, M., et al. (2010). Tumor-medi-
ated liver X receptor-alpha activation inhibits CC chemokine receptor-7
expression on dendritic cells and dampens antitumor responses. Nat. Med.
16, 98–105.
Wagner, B.L., Valledor, A.F., Shao, G., Daige, C.L., Bischoff, E.D., Petrowski,
M., Jepsen, K., Baek, S.H., Heyman, R.A., Rosenfeld, M.G., et al. (2003).
Promoter-specific roles for liver X receptor/corepressor complexes in the
regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 23,
5780–5789.
Wang, Y., Rogers, P.M., Su, C., Varga, G., Stayrook, K.R., and Burris, T.P.
(2008). Regulation of cholesterologenesis by the oxysterol receptor,
LXRalpha. J. Biol. Chem. 283, 26332–26339.
Warburg, O., Wind, F., and Negelein, E. (1927). The Metabolism of Tumors in
the Body. J. Gen. Physiol. 8, 519–530.
Wo´jcicka, G., Jamroz-Wisniewska, A., Horoszewicz, K., and Be1towski, J.
(2007). Liver X receptors (LXRs). Part I: structure, function, regulation of activ-
ity, and role in lipid metabolism. Postepy Hig Med Dosw (Online) 61, 736–759.56 Cancer Cell 28, 42–56, July 13, 2015 ª2015 Elsevier Inc.Yeung, S.J., Pan, J., and Lee, M.H. (2008). Roles of p53, MYC and HIF-1 in
regulating glycolysis - the seventh hallmark of cancer. Cell. Mol. Life Sci. 65,
3981–3999.
Zaytseva, Y.Y., Rychahou, P.G., Gulhati, P., Elliott, V.A., Mustain, W.C.,
O’Connor, K., Morris, A.J., Sunkara, M., Weiss, H.L., Lee, E.Y., and Evers,
B.M. (2012). Inhibition of fatty acid synthase attenuates CD44-associated
signaling and reduces metastasis in colorectal cancer. Cancer Res. 72,
1504–1517.
Zhang, Y., Zhang, X., Chen, L., Wu, J., Su, D., Lu, W.J., Hwang, M.T., Yang, G.,
Li, S., Wei, M., et al. (2006). Liver X receptor agonist TO-901317 upregulates
SCD1 expression in renal proximal straight tubule. Am. J. Physiol. Renal
Physiol. 290, F1065–F1073.
Zhao, L.F., Iwasaki, Y., Nishiyama, M., Taguchi, T., Tsugita, M., Okazaki,
M., Nakayama, S., Kambayashi, M., Fujimoto, S., Hashimoto, K., et al.
(2012). Liver X receptor a is involved in the transcriptional regulation of
the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. Diabetes
61, 1062–1071.
